Handheld, AI-powered device brings hospital-grade heart tests into the palm of a clinician’s hand and closer to patients across Europe.
What if the test that could save your life didn’t need a hospital? Picture this: a patient walks into a small clinic, uneasy, short of breath. In most cases, confirming whether it’s something serious (like a heart attack) means hooking them up to a bulky machine, attaching wires across their chest and waiting. Time stretches. Decisions stall. ECG-specializing medtech company AliveCor is trying to compress that entire moment.
With its newly CE-marked Kardia 12L, now launching across Europe, the company is betting that one of medicine’s most essential tests can be made faster, simpler and far more accessible without losing the depth doctors rely on [1].
A traditional 12-lead ECG is the gold standard for reading the heart’s electrical signals. It’s also, frankly, inconvenient. The machines are large, the setup is time-consuming, and they’re mostly confined to hospitals or well-equipped clinics.
Kardia 12L flips that model. It’s small enough to hold, light enough to carry anywhere and runs on a battery. Instead of a web of wires, it uses a single cable and five electrodes – guided by built-in AI – to capture the same kind of information doctors would expect from a full setup. It’s not replacing the ECG; it’s more like compressing it – like how smartphones didn’t invent cameras, but made them available everywhere.
AliveCor’s Kardia 12L has officially received its CE Mark, marking a significant milestone in the company’s efforts to expand its medical-grade heart monitoring technology across global markets.
“Our priority is to get this life-saving technology into the hands of as many clinicians as possible, especially in settings where traditional, bulky ECG carts simply aren’t practical. By simplifying the hardware without sacrificing diagnostic depth, we are fundamentally improving access to high-quality cardiac care and reducing the burden of cardiovascular disease in the EU,” said Simona Esposito, Senior Vice President of Sales, Global Markets at AliveCor.
When it comes to heart conditions, delays are as frustrating as dangerous. The longer it takes to confirm a diagnosis, the longer it takes to act. Kardia 12L is designed to shave off that time. The system can detect 35 different cardiac conditions, including heart attacks and common forms of reduced blood flow to the heart. More importantly, it does so quickly, cutting down test time by nearly a third.
The AI behind it acts like a second set of eyes, helping clinicians interpret signals in real time. Not to replace judgment, but to accelerate it.
Dr Alejandro Barbagelata, an Adjunct Assistant Professor of Medicine and Cardiology at Duke University, emphasized that while every second is critical in a fast-paced clinical environment, the pursuit of speed must not come at the expense of accuracy.
“Kardia 12L offers a unique combination of portability and diagnostic depth, allowing HCPs to make informed care decisions. By streamlining the acquisition process, it enables clinicians to identify life-threatening conditions like MI much faster, leading to better patient outcomes across the board,” he said.
Patient experience is also changing. With fewer electrodes and a simpler setup, patients don’t need to fully undress for the test. It’s faster, less invasive and arguably more humane.
Since its US debut in 2024, Kardia 12L has already been used on tens of thousands of patients worldwide, identifying more than 4,000 cases of heart attack and ischemia. Now, the real story isn’t just about making ECGs portable; it’s about where those ECGs can now go. Primary care clinics. Rural outposts. Pharmacies. Even in patients’ homes, when a clinician is present. Places where early signs of heart disease often surface, but where advanced diagnostics haven’t always followed.
Europe, where cardiovascular disease remains the leading cause of death, is an obvious next step. The rollout across France, Germany, Italy, Spain and the United Kingdom aligns with a broader push toward earlier detection and prevention.
In longevity, most conversations focus on breakthrough therapies or futuristic interventions, but just as critical (and often overlooked) is the moment of detection. Catching a problem earlier improves outcomes and reshapes the entire trajectory of aging.
Devices like Kardia 12L live in that space. They don’t extend life on their own, but they make it more likely that life-extending care happens when it still can. That’s where the nuance lies. Faster diagnostics don’t automatically fix healthcare systems. Access still depends on infrastructure, training and cost. However, they do remove one of the most persistent barriers: delay. If the past decade was about making health data digital, this one may be about making it immediate.
AliveCor’s handheld ECG is a small device with an ambition to close the distance between noticing something is wrong and knowing what to do about it. In longevity terms, that distance can be the difference between years gained and years lost. Sometimes, it’s about taking something we already know works and making sure it shows up exactly where it’s needed, exactly when it matters.
Photographs courtesy of AliveCor
[1] https://alivecor.com/press/press_release/ai-powered-kardia-12l-in-europe
